摘要
HER2 is a pillar biomarker in breast cancer,and it is assessed by immunohistochemistry(IHC)using a three-tier scoring system and reflex in situ hybridization(ISH)for IHC score 2+.Novel HER2-directed antibody-drug conjugates have demonstrated significant antitumor activity in breast cancers with low levels of HER2 expression,i.e.IHC score 1+or ISH-negative IHC score 2+.Both primary and acquired resistance to anti-HER2 therapies remains a challenge in the treatment of breast cancers according to the HER2 positivity continuum.Thus,the ability to precisely discriminate among HER2-zero,HER2-low,and HER2-positive breast cancers is no longer a mere academic exercise.HER2 testing criteria,guidelines,and quality controls are re-gaining momentum for this new clinical need.Therefore,all preanalytical and analytical variables that might trouble the sensitivity and reproducibility of this test should be carefully considered to address all possible issues and open all possible therapeutic opportunities for breast cancer patients.
